<< Read Full Article
<< Read Full Article
Dendreon's Got Miles to Go With Provenge
A version of this column was previously published to subscribers of the Biotech Select newsletter. If you're interested in subscribing, please click here for more information.
I want to conduct a postmortem on my Dendreon(DNDN Quote) call. I was right on the Provenge interim analysis, but came up wrong on the stock.
As I expected, the interim analysis of the Provenge study failed: The data were not strong enough to stop the study early. The stock should have dropped. Instead, Dendreon shares rose 33% Monday because the company surprised us all by releasing what looked like promising Provenge survival data from the study. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,471.50 | 1,106.41 | 2,190.31 | 35.40 |
Oil *
71.66
|
|
UP
65.67
|
UP
4.06
|
DOWN
0.55
|
UP
0.58
|
10 Yr
3.54%
SPDR Gold
109.32
|
|
+0.63%
|
+0.37%
|
-0.03%
|
+1.67%
|
Data delayed 20 minutes |
Connect with TheStreet